During his brief bid to become the Republican presidential nominee in 2023, Ramaswamy invoked his biotech credentials to ...

This week’s slate of Democratic winners have set their sights on expanding healthcare, removing RFK Jr. from HHS and pulling ...

Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these ...

The investor narrative around Eli Lilly is deeply rooted in obesity. The blockbuster GLP-1 medications Mounjaro and Zepbound are driving the large pharma’s gains in revenue, which rose 39% ...

After incubating about 1,200 companies, the pharma giant is putting less emphasis on physical lab space — and taking a more ...

Over the last few years, digital transformation has become one of the most widely discussed topics in biopharma manufacturing. Automation, advanced analytics, digital twins, the use of artificial ...

Pharmaceuticals enable modern healthcare by helping to prevent, manage, and cure disease, but growing demand is increasing their impact on the environment. For oral drug delivery, medicines must be ...

The dreaded patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its ...